COMP-Ang1稳定高糖对人视网膜微血管内皮细胞血视网膜屏障表型的破坏
该体外细胞研究在人视网膜微血管内皮细胞(HRMvEC)模型中,用30 mM d-葡萄糖破坏屏障完整性,评估工程化血管生成素-1变体COMP-Ang1(10–200 ng/mL)的保护作用。结果显示COMP-Ang1浓度依赖性减轻高糖诱导的通透性升高和紧密连接/黏附连接蛋白下调,200 ng/mL可恢复屏障功能约88%,该效应依赖Tie2受体信号。
要点
- 30 mM d-葡萄糖(非l-葡萄糖)时间依赖性增加HRMvEC单层对FITC-右旋糖酐40 kDa的通透性。
- COMP-Ang1浓度依赖性减轻高糖诱导的通透性升高及occludin、claudin-5、ZO-1、VE-Cadherin的mRNA/蛋白下调。
- Tie2小干扰RNA沉默阻断COMP-Ang1的保护作用,提示其经Tie2介导信号发挥效应。
核心结论
- 本文呈报一项可重复的体外细胞研究,量化COMP-Ang1经Tie2介导信号浓度依赖性减轻高糖对HRMvEC屏障特性的损伤效应。
研究设计与样本
- 体外细胞研究:融合的HRMvEC分别以5或30 mM d-葡萄糖处理0–72小时,并设30 mM l-葡萄糖渗透压对照。
- COMP-Ang1按10–200 ng/mL浓度加入,检测FITC-右旋糖酐40 kDa通透性及内皮连接靶点的RT-qPCR和Western blotting。
- 另用受体酪氨酸激酶Tie2基因沉默评估其对COMP-Ang1效能的影响。
主要发现
- 30 mM d-葡萄糖(而非l-葡萄糖)时间依赖性升高FITC-右旋糖酐跨HRMvEC单层平均扩散速率。
- 同期occludin、claudin-5、ZO-1和VE-Cadherin的mRNA/蛋白水平显著降低。
- COMP-Ang1浓度依赖性减轻上述效应,200 ng/mL使屏障功能恢复约88%,并使降低的内皮连接蛋白水平恢复超过50%。
- Tie2小干扰RNA沉默阻断COMP-Ang1减轻高糖诱导的HRMvEC通透化及连接表达耗竭的能力。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Current treatments for diabetic retinopathy (DR) have considerable limitations, underpinning the need for new therapeutic options. In this article, the ability of an engineered angiopoietin-1 variant (COMP-Ang1) to ameliorate the injurious effects of hyperglycemia on barrier integrity in a human retinal microvascular endothelial cell (HRMvEC) model is comprehensively investigated. METHODS: Confluent HRMvECs were treated (0-72 hours) with d-glucose (5 or 30 mM) in the absence and presence of COMP-Ang1 (10-200 ng/mL). l-glucose (30 mM) was used as osmotic control. Posttreatment, intact cell monolayers were monitored for permeability to FITC-dextran 40 kDa. Cells were also harvested for analysis of interendothelial junction targets by RT-qPCR and Western blotting. The impact of receptor tyrosine kinase Tie2 gene silencing on COMP-Ang1 efficacy was also evaluated. RESULTS: Treatment with 30 mM d-glucose (but not l-glucose) demonstrated a time-dependent elevation in the mean rate of FITC-dextran diffusion across intact HRMvEC monolayers, in parallel with significant reductions in mRNA/protein levels of occludin, claudin-5, ZO-1, and VE-Cadherin. These effects were all attenuated by COMP-Ang1 in a concentration-dependent fashion, with 200 ng/mL recovering barrier function by ∼88%, and recovering reduced interendothelial junction protein levels by more than 50%. Finally, Tie2 knockdown by small interfering RNA silencing blocked the ability of COMP-Ang1 to mitigate against hyperglycemia-induced permeabilization of HRMvECs and depletion of junctional expression levels. CONCLUSIONS: In summary, this article presents a reproducible in vitro cell study that quantifies the concentration-dependent efficacy of COMP-Ang1 to mitigate the injurious effects of hyperglycemic challenge on HRMvEC barrier properties via Tie2-mediated signaling.
引用
- Rochfort KD, Carroll LS, Barabas P, et al. COMP-Ang1 Stabilizes Hyperglycemic Disruption of Blood-Retinal Barrier Phenotype in Human Retinal Microvascular Endothelial Cells. Invest Ophthalmol Vis Sci. 2019. PMID: 31415078. doi:10.1167/iovs.19-27644
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。